Gene markers for lung cancer
View Patent ↗A method for the diagnosis and identification of new or residual lung cancer is disclosed which uses newly identified markers for lung cancer including syndecan 1, collagen 1 alpha 2, and two novel proteins, 7013 and 7018. The method involves identification of the lung cancer markers is blood from a patient. It is envisioned that at least one marker may be used or any mixture of the four. The method may also include the identification of cytokeratin-19.
1. An isolated or purified polynucleotide consisting of SEQ ID NO: 16.
2. An isolated or purified polynucleotide fragment of SEQ ID NO: 16 consisting of at least 17 consecutive nucleotides of SEQ ID NO: 16 or the complement thereof.
3. A method for the identification of lung cancer in a human patient comprising:
isolating blood from a human patient,
identifying the presence of a polynucleotide consisting of SEQ ID NO: 16 wherein the presence of SEQ ID NO: 16 is indicative of lung cancer.
4. The method of claim 1 , further comprising identifying the presence of the marker cytokeratin-19.
5. The method of claim 1 , wherein at least two markers are identified.
6. The method of claim 4 , wherein more than two markers are identified.
7. The method of claim 1 wherein said identification is by RT-PCR.
8. A method for the identification of metastases of a lung tumor in a human patient comprising:
isolating blood from a human patient,
identifying the presence of a polynucleotide consisting of SEQ ID NO: 16 wherein the presence of SEQ ID NO: 16 is indicative of metastases of lung cancer.
9. The method of claim 8 , wherein said metastases of a solid tumor is selected from the group consisting of bile duct, colon, breast, uterus, esophagus, and larynx.
10. A plasmid p7013, having ATCC accession number PTA-3471.
11. A plasmid p7013/12, having ATCC accession number PTA-3473.